Preview

Russian journal of hematology and transfusiology

Advanced search

Risk factors for recurrence of cytomegalovirus retinitis in children receiving allogeneic hematopoietic stem cell transplantation

https://doi.org/10.35754/0234-5730-2025-70-3-311-319

Abstract

Introduction. Cytomegalovirus retinitis (CMVR) is a necrotizing disease of the retina that can cause irreversible blindness. An increase in the number of CMVR episodes increases the likelihood of developing irreversible blindness. Reducing the risk of CMVR recurrence will improve the effectiveness of visual rehabilitation for this category of patients. Aim: To study the patterns and risk factors for the development of CMVR recurrence in children who are recipients of hematopoietic stem cells.

Materials and methods. The study included 37 patients aged 0 to 21 years (62 eyes) who had undergone CMVR and hematopoietic stem cell transplantation and received a series of intravitreal injections (IVI) of antiviral drugs. CMVR recurrences occurred in seven patients. In 3 patients, there was a recurrence in 1 eye, in 4 — in both eyes. Of the 62 eyes, 51 had no recurrences, 6 had one recurrence, and 5 had more than one recurrence. A recurrence was diagnosed in 23 out of 81 episodes. Remission was considered achieved when the absence of cytomegalovirus DNA was confi rmed in a sample of aqueous humor taken from the anterior chamber of the eye and/or upon complete healing of CMVR lesions as determined by ophthalmoscopy.

Results. Discontinuation of IV antiviral drugs based on negative aqueous humor PCR results reduces the likelihood of recurrence by more than 16 times compared to a decision based on ophthalmoscopic data (p-value = 0.011) and by more than 2 times compared with non-zero PCR results.

Conclusion. The recurrent nature of the course of CMVR is associated with the replication of virus copies inside the eye. Elimination of copies of the virus from the intraocular fl uid reduces the likelihood of developing a CMVR recurrence.

About the Authors

B. S. Pershin
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation

Boris S. Pershin, Cand. Sci. (Med.), ophthalmologist

117198, Moscow



A. A. Maschan
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation

Alexei A. Maschan, Dr. Sci. (Med.), Professor, corresponding member of the RAS, Deputy Director

117198, Moscow



A. B. Smirnova
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation

Anna B. Smirnova, ophthalmologist

117198, Moscow



References

1. Keijer W.J., Burger D.M., Neuteboom G.H., et al. Ocular complications of the acquired immunodefi ciency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharm World Sci. 1993;15(2):56–67. DOI: 10.1007/BF01874084.

2. Iu L.P., Fan M.C., Lau J.K., et al. Long-term follow-up of cytomegalovirus retinitis in non-HIV immunocompromised patients: Clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53. DOI: 10.1016/j.ajo.2016.03.015.

3. Jeon S., Lee W.K., Lee Y., et al. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell trans-plantation. Ophthalmology. 2012;119(9):1892–8. DOI: 10.1016/j.ophtha.2012.03.032.

4. Kotton C.N., Kumar D., Caliendo A.M., et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60. DOI: 10.1097/TP.0b013e31829df29d.

5. Ariza-Heredia E.J., Nesher L., Chemaly R.F. Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review. Cancer Lett. 2014;342(1):1– 8. DOI: 10.1016/j.canlet.2013.09.004.

6. Mizushima D., Nishijima T., Gatanaga H., et al. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era. PLoS One. 2013;8(5):e65348. DOI: 10.1371/journal.pone.0065348.

7. Voigt S., Michel D., Kershaw O., et al. Fatal reactivation of postnatal cytomegalovirus infection with rapid emergence of ganciclovir resistance in an infant after allogeneic stem cell transplantation. J Clin Microbiol. 2005;43(7):3551–4. DOI: 10.1128/JCM.43.7.3551-3554.2005.

8. Jabs D.A., Van Natta M.L., Kempen J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133(1):48–61. DOI: 10.1016/s0002-9394(01)01322-8.

9. Jacobson M.A., O’Donnell J.J., Brodie H.R., et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol. 1988;25(3):339–49. DOI: 10.1002/jmv.1890250311.

10. Crumpacker C.S. Ganciclovir. N Engl J Med. 1996;335(10):721–9. DOI: 10.1056/NEJM199609053351007.

11. Drew W.L., Ives D., Lalezari J.P., et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333(10):615–20. DOI: 10.1056/NEJM199509073331002.

12. Teoh S.C., Ou X., Lim T.H. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: Effi cacy of a low-volume, intermediate-dose regimen. Ophthalmology. 2012;119(3):588–95. DOI: 10.1016/j.ophtha.2011.09.004.

13. Singh S.R., Dogra M., Kaur S., et al. Spectrum of newly diagnosed cytomegalovirus retinitis in a developing country in the HAART era. Ocul Immunol Infl amm. 2020;28(1):119–25. DOI: 10.1080/09273948.2018.1538460.

14. Crippa F., Corey L., Chuang E.L., et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32(2):214–9. DOI: 10.1086/318447.


Review

For citations:


Pershin B.S., Maschan A.A., Smirnova A.B. Risk factors for recurrence of cytomegalovirus retinitis in children receiving allogeneic hematopoietic stem cell transplantation. Russian journal of hematology and transfusiology. 2025;70(3):311-319. (In Russ.) https://doi.org/10.35754/0234-5730-2025-70-3-311-319

Views: 90


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0234-5730 (Print)
ISSN 2411-3042 (Online)